BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Steglatro (Ertugliflozin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Steglatro (Ertugliflozin)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07621380-309@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Steglatro (Ertugliflozin): Phase 4 readout est. (NCT07621380)
DESCRIPTION:Steglatro (Ertugliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: 
 Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocar
 dial Infarction\nEstimated primary completion: 1 January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ertugliflozin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07621380
URL:https://assetmemo.bio/drug/ertugliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07547878-309@assetmemo.bio
DTSTAMP:20261121T005642Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Steglatro (Ertugliflozin): Phase 4 readout est. (NCT07547878)
DESCRIPTION:Steglatro (Ertugliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: 
 Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies
  (RAPID-CKD)\nEstimated primary completion: 31 March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ertugliflozin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07547878
URL:https://assetmemo.bio/drug/ertugliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
